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Abstract 
 
In meta-analyses, where a continuous outcome is measured with different scales or 
standards, the summary statistic is the mean difference standardised to a common 
metric with a common variance. Where trial treatment is delivered by a person, 
nesting of patients within care providers leads to clustering that may interact with, or 
be limited to, one or more of the arms. Assuming a common standardising variance is 
less tenable and options for scaling the mean difference become numerous. Metrics 
suggested for cluster-randomised trials are within, between and total variances. For 
unequal variances, the control arm or pooled variances. We consider summary 
measures and individual-patient-data (IPD) methods for meta-analysing standardised 
mean differences (SMDs) from trials with two-level nested clustering, relaxing 
independence and common variance assumptions, allowing sample sizes to differ 
across arms. A general metric is proposed with comparable interpretation across 
designs. The relationship between the method of standardisation and choice of model 
is explored, allowing for bias in the estimator and imprecision in the standardising 
metric. A meta-analysis of trials of counselling in primary care motivated this work. 
Assuming equal clustering effects across trials, the proposed random-effects meta-
analysis model gave a pooled SMD of -0.27 (95% CI -0.45 to -0.08) using summary 
measures and -0.26 (95% CI -0.45 to -0.09) with the IPD. While treatment-related 
clustering has rarely been taken into account in trials, it is now recommended that it is 
considered in trials and meta-analyses. This paper contributes to the uptake of this 
guidance. 
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1. INTRODUCTION 
6XPPDU\PHDVXUHVDSSURDFKHVWRVWDWLVWLFDOSRROLQJRUµPHWD-DQDO\VLV¶RIUDQGRPLVHG
trials first involve extracting a summary statistic, representing a treatment effect, from 
each trial and then calculating a weighted average of them [1, 2]. Where the outcome 
is normally-distributed, for example the severity of depression, the summary statistic 
is often an absolute mean difference. If the outcome is measured with different scales 
or standards across trials, for instance with the HADS-D [3], PHQ-9 [4] and the BDI 
[5], then the relevant summary statistic is the absolute mean difference, standardised 
to a common metric. That is, the standardised mean difference (SMD) or effect size. 
Outcomes are then assumed to be linearly equitable across trials, regardless of the 
measurement tool used, and the summary statistic is interpreted as a mean difference 
given in units of a standard deviation (SD) [6]. Where outcomes can be assumed to be 
independent and their SD homogeneous, the population SMD is defined as the 
difference in means across arms, divided by the common SD of the outcome. 
 
Independence and common variance assumptions are less tenable when the treatment 
a patient receives is delivered by a health professional, such as in talking or physical 
therapies or surgery. Systematic variation RUµcOXVWHULQJ¶ in patient outcomes by care 
provider arises when providers differ in characteristics related to outcome, such as 
training, skill, experience or empathy. As with cluster-randomised trials, the resulting 
correlation among outcomes within clusters violates the assumption of independence. 
However, treatment-related clustering also violates the common variance assumption. 
Provider characteristics may also differ across arms, for instance with greater skill or 
different training being required for one treatment than another. There may also be 
greater standardisation of one treatment, or one may be more established so that there 
is greater experience associated with it. The consequence of violations to the standard 
assumptions is that there is no longer a single common metric; the options available 
for scaling the mean difference being numerous. In general, each one is associated 
with a different population parameter and requires a different interpretation. 
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In cluster-randomised trials, typically, treatments are randomly allocated to entire 
clusters in a fully-nested, parallel-group design [7]. It is generally assumed that the 
clustering effect is homogeneous across treatment arms so the between- and within-
cluster variances, which make up the total variance, are the same in both arms and a 
random intercept model appropriate for the analysis of each trial. Under this 
assumption, both White and Thomas [8] and Hedges [9] have suggested population 
SMDs based on the between, within and total SDs respectively. A between-cluster SD 
cannot be defined if there is only one cluster per arm in a trial. Similarly, where 
cluster-level analyses are reported, the within-cluster SD may not be. In both cases it 
would be possible to make assumptions about the intra-cluster correlation (ICC) and 
report and interpret the SMD in units of the total SD. While the choice of metric 
should depend on the inference of interest to a meta-analyst [9], SMDs based on the 
total and within SDs reduce to the standard SMD when outcomes are independent. If 
clustering is ignored in the published analyses, estimates of the between, within, and 
total SDs are unlikely to be readily available. Therefore, their population values may 
be difficult to estimate directly. To circumvent this problem, White and Thomas [8] 
and Hedges [9] suggest replacing the total SD by a µnaïve¶ SD, given by the total 
mean squares, in estimating the total SD SMD, and correcting for a bias that arises in 
doing so. 
 
The simple situation, in which independence and normality assumptions hold but the 
variances differ across two treatment arms, is classically referred to as the Behrens-
Fisher problem [10]. Glass [11] argued that between-trial heterogeneity in the 
treatment arms obscures interpretation when pooling trials in this situation and 
recommended the control arm SD be used as the metric of choice if the comparator is 
no treatment. It is arguable that this advantage is lost if control content also varies 
from trial to trial. As an alternative, Huynh [12] suggested pooling the SDs across 
arms, using the effect size proposed by Cohen [13, p.44]. In contrast to the standard 
SD, sample SDs in this metric estimate different population SDs. While it has been 
argued that the resulting distribution is rather contrived, and requires careful 
interpretation [14], this SMD has the advantage of reducing to the standard SMD 
when the outcome SDs are homogeneous across arms, utilising all available outcome 
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data, and minimises the small-sample bias in the trial SMDs identified by Hedges [6, 
15]. Huynh [12] assumed the sample size is the same in each arm. Where it differs, as 
is often the case, we propose a more general pooled outcome SD that could be used, 
weighting the SDs by the sample size in each arm. A further option might be to use 
the associated baseline SD, a metric more commonly recommended for standardised 
mean change scores [16-20]. This may appeal particularly where eligibility criteria are 
similar across studies. 
 
Use of individual-patient-data (IPD) in meta-analyses of SMDs appears to be limited, 
but see [21-23] for examples. Goldstein et al [24] described an IPD approach with the 
level-1 or within-cluster SD as the common metric. This was illustrated using studies 
of class size where students were nested within classes, schools and studies, and small 
versus large class size represented the treatment arms. The inclusion of a further level 
in the meta-analysis makes their approach especially relevant but, in contrast, schools 
are crossed with arms in their example. And, while they allude to models that allow 
for between-arm or trial heteroscedasticity, they do not consider nested study designs, 
the rationale or implications of the choice of metric, imprecision in the standardising 
SD, or the relationship between the method for standardising outcome data and the 
choice of model for the meta-analysis. 
 
This paper proposes summary measures and IPD approaches to the meta-analysis of 
standardised mean differences from randomised trials with uniform two-level nested 
designs and treatment-related clustering. It builds on earlier work [25], addressing the 
simpler situation in which absolute mean differences are to be pooled, but due to the 
additional complexities here, between-trial homogeneity in the within-trial clustering 
effects is assumed throughout. In both papers, the nested designs considered assume 
there is a single therapist-per-patient. In a fully nested design different care providers 
deliver every treatment, while at least one treatment does not require care providers in 
a partially nested design (see Walwyn and Roberts [26] for further description of the 
full range of therapist designs). The statistical model recommended at the trial-level 
for both nested designs is a two-level heteroscedastic model [27]. This includes a 
random effect for the care provider but allows the provider and patient level variances 
6 
 
to differ across arms, constraining the provider variance to zero in arms with no care 
providers for partially nested designs.  
 
We begin in section 2 by outlining the example that motivated this work. In section 3 
we set out the summary measures approach proposed by Hedges [6, 15], highlighting 
the steps involved a standard meta-analysis of SMDs and how it differs from a meta-
analysis of absolute mean differences. In section 4 we extend this approach, and those 
suggested by White and Thomas [8], Hedges [9] and Huynh [12], proposing a general 
metric that simultaneously relaxes independence and between-arm common variance 
assumptions, also allowing the number of patients to differ across arms. In section 5 
we first outline the steps suggested by Goldstein et al [24] for a standard IPD meta-
analysis of SMDs, highlighting how these could be modified to allow for imprecision 
in the standardising metric. We then extend them, initially relaxing the between-arm 
homoscedasticity assumption for the Behrens-Fisher case, and then simultaneously 
relaxing the independence and between-arm homoscedasticity assumptions necessary 
to pool trials with treatment-related clustering. In section 6 we illustrate our methods 
using our motivating example, concluding in section 7 with a discussion and 
limitations. 
 
2. MOTIVATING EXAMPLE 
As in our previous paper on the meta-analysis of absolute mean differences [25], we 
were motivated by %RZHUDQG5RZODQG¶V[28] systematic review of the clinical and 
cost-effectiveness of counselling in UK primary care, which included 8 trials. As it is 
usual for counsellors to apply eclectic therapeutic approaches to a very wide range of 
social and clinical problems, the implications of therapist variation [26] are especially 
pertinent in this setting. The largest meta-analysis involved 7 trials [29-35] comparing 
counselling plus care from a general practitioner (GP) to just GP care using short term 
outcomes measuring the level of mental health symptoms.  
 
Four of these trials [30, 31, 34, 35] reported the Beck Depression Inventory (BDI) [5], 
allowing a meta-analysis of the absolute mean differences [25]; the other three trials 
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[29, 32, 33] reported the General Health Questionnaire (GHQ) [36], the depression 
subscale of the Hospital Anxiety and Depression Scale (HADS-D) [3] and a short 
Symptom Index, respectively. All are commonly used self-report questionnaires: the 
BDI and the HADS-D measure severity of depression while the GHQ and Symptom 
Index are global measures of wellbeing. The BDI has 21 items (total scores 0 to 63) 
and the HADS has 7 items relating to depression (subscale scores 0 to 21) with higher 
scores indicating greater severity. The GHQ had 28 items (total scores 0 to 28) with a 
score above 4 indicating the presence of distress. The Symptom Index had 18 items 
(mean scores 0 to 4) with a norm of 0.61. Across these scales, a change of 0.5 SDs is 
generally regarded minimally important.  
 
To pool all 7 trials, it was necessary to first transform the data on all four scales to a 
common metric. The published meta-analysis [28] gave an SMD of -0.24 SDs (95% 
CI -0.38 to -0.10), soDFFRUGLQJWR&RKHQ¶V[13] classification, the pooled treatment 
effect can be regarded as clinically small but statistically significant. Authors of the 
&RFKUDQHUHYLHZFRQFOXGHGµFRXQVHOOLQJLVDVVRFLDWHG with modest improvement in 
short-WHUPRXWFRPH¶DQGWKDWLWµPD\EHDXVHIXODGGLWLRQWRPHQWDOKHDOWK services in 
primary FDUH¶[37]. Ignoring the co-intervention of GP care, each trial can be viewed 
as having a partially nested design, with counsellors delivering treatment in the 
intervention but not in the control arm. Across trials, there was a single counsellor per 
patient. The published meta-analysis used a standard summary measures approach, 
assuming independence of patient outcomes within trials and a common variance 
across arms, fitting a fixed-effects meta-analysis model assuming a common 
underlying SMD across trials. 
 
3. THE STANDARD SUMMARY MEASURES APPROACH  
Any summary measures meta-analysis of SMDs, or absolute mean differences for that 
matter, requires the systematic reviewer to assume outcomes are normally-distributed 
and to extract the sample means ( khy ), SDs ( khs ) and sizes ( khn ) for each arm 
( 1,0 k ) of every trial ( Hh ,,1 ). Assuming these are all available from 
published or unpublished trial reports or direct correspondence with authors, the first 
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step is to choose an appropriate metric or SD for scaling the absolute mean difference. 
The SMD is thus a ratio, where the absolute mean difference is not. In the standard 
but also simplest scenario, where independence and homoscedasticity is assumed 
within and across each trial to be pooled, there is only one option for such a metric, 
the common SDV . The population SMD is therefore defined [6, 15] as 
V
PPT 01  SMD  (1) 
 
with the difference in population means of the treatment and control arm respectively 
in the numerator and a common standardising metric in the denominator. The second 
step specific to meta-analyses of SMDs is to choose an estimator for the denominator. 
Usually the population metric can be estimated, within each trial, by the sample SD in 
the treatment or control arm, hs1 , hs0  or by the sample SD pooled across arms, hsx . A 
third step is then to determine the sampling distribution for the chosen estimator of 
the denominator of the SMD, obtaining the relevant degrees of freedom. This tends to 
be the pooled sample SD hsx  because it maximises the degrees of freedom available, 
utilising all of the available data. As in the standard case the pooled sample variance 
is simply the mean squares error, that is hh MSEs  x2 , it follows that its sampling 
distribution is exactly proportional to a chi-square with 201  hh nn  degrees of 
freedom hdf . Since hsx is a direct estimator of V in the standard case, a fourth step of 
calculating a bias, relating to the choice of estimator for the metric, is avoided. Once 
one has a sampling distribution for the standardising metric, a fifth step, which is 
common to all meta-analyses, is to obtain the sampling distribution of the sample 
estimate of the population parameter so as to select an unbiased summary statistic and 
determine its standard error. There are two sample estimates of the population SMD. 
In the standard case, the first is commonly referred to as &RKHQ¶V d  [13], the second 
as +HGJHV¶ g [15]. &RKHQ¶V d is the large-sample estimate of the population SMD and 
is given by simply replacing the population parameters by their sample equivalents in 
each trial as follows, 
h
hh
hdsCohen
s
yy
x
 01
,'
ÖT      (2) 
9 
 
 
This makes no allowance for imprecision in the standardising SD, instead assuming 
that all the trial sample sizes are large so all the hdf  are also large. Its sampling 
distribution is given asymptotically [15] by 
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As &RKHQ¶V d  is a ratio of a mean difference to a standardising SD, its standard error 
is equal to the standard error of the absolute mean difference plus a term that relates to 
the SD, the latter depending on the population parameter. As such, in contrast to a 
meta-analysis of absolute mean differences, in a meta-analysis of SMDs, the sample 
estimate and its standard error can be seen to depend on the variance of the outcome. 
If any of the trial sample sizes ( hnx ) are small, and particularly if hdf 10d , Hedges 
[15] VKRZHGWKDW&RKHQ¶V d  is biased for SMDT , and derived an alternative estimator, 
to correct for this, 
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+HGJHV¶ g is the unbiased estimate of the population SMD, appropriate regardless of 
the degrees of freedom, hdf , available for estimating the standardising metric, 2hsx . It is 
therefore SUHIHUUHGRYHU&RKHQ¶V d . HeGJHV¶ g  FRQYHUJHVWR&RKHQ¶V d  as the trial 
sample sizes increase EXWLVXQLIRUPO\VPDOOHUWKDQ&RKHQ¶V d otherwise [15]. Since 
Hedges [6, 15] originally suggested substituting 2
,'
Ö
hgHedgesT  for 2SMDT  when estimating 
the standard error, this is widely done in software. White and Thomas [8, p.150] 
showed that this introduces bias because the expectation of a squared estimate is equal 
to the squared parameter plus the variance of the estimate, not simply the squared 
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parameter (that is   2Ö22Ö TVTT  E ). So they proposed a refined estimator for the exact 
sampling variance, given by 
 
  ¸¸¹
·
¨¨©
§ ¸¸¹
·
¨¨©
§  
hh
h
hgHedges
hh dfdfc
df
nnhgHedges 2
2
,'
01
2
Ö
21Ö11Ö
,'
TVT       (5) 
 
The first term clearly relates to the variance of the numerator of the trial SMD and the 
second to the variance of its denominator. This was originally derived by Hedges [38 
p.391]. 
 
Again common to all meta-analyses, once one has an unbiased summary statistic (e.g. 
Equation (4)) and an unbiased estimate of its standard error (e.g. Equation (5)) a sixth 
step is to pool summary statistics using fixed or random-effects meta-analysis models 
[39]. The choice between a fixed or random-effects meta-analysis is based on whether 
it is reasonable to assume there is an underlying SMD common across trials. If it is, a 
fixed effects model may be fitted. In the more likely scenario where population SMDs 
vary across trials, a random-effects model should be fitted. Where there is substantial 
heterogeneity in SMDs across trials, it is important to explore possible explanations 
for this, perhaps in the context of a meta-regression [40], or give a tolerance interval 
for the effect in a new study [41]. Methods to allow for between-trial heterogeneity 
are beyond the scope of this paper, however. The uniformly minimum variance 
unbiased estimate (UMVUE) of any pooled treatment effect T  is given by the 
following weighted average [42, 43] 
¦
¦
 
  H
h
h
H
h
hh
w
w
1
1
Ö
Ö
T
T       (6) 
where the trial weights, hw , are the inverse of the sampling variance of the summary 
statistic. In a random-effects meta-analysis model, the weights are the inverse of the 
total sampling variance, given by the sum of the within, 2Ö
,'
Ö
hgHedgesTV , and between, 2Ö LDW , 
trial variances, where the latter is often estimated using DerSimonian-/DLUG¶V'-L) 
[44] methods of moments estimator. In a fixed-effects meta-analysis the between trial 
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variance is simply zero. It is usual for 
2
Ö
hTV  and 2hTW  to be replaced by their respective 
estimators
2
ÖÖ
hTV  and 2Ö hTW  here, although Sidik and Jonkman [45] suggest an alternative 
approach that is robust to sampling errors in the estimated weights.  
 
A seventh step, recommended for summary measures SMD meta-analyses [6] but 
unnecessary when the summary statistic is an absolute mean difference, is to plug the 
pooled estimate of the population SMD from Equation (6) back into the estimate of 
the within trial variance given in Equation (5), which is used in estimating the trial 
weights, hw , and to continue iterating until convergence. While this step is not always 
implemented in software, and it may not be desirable where there is any suspicion of 
heterogeneity in the SMD across trials, it is important because the initial weights 
depend on the trial estimate of the SMD. As the size of the weights increase as a 
function of SMD, particularly if the degrees of freedom available for estimating the 
standardising SD are low, omitting this step may lead to the pooled treatment effect 
being unduly affected by a single trial with an extreme SMD. Hedges [6] argued that 
when the degrees of freedom relating to the standardising SD are all large this step 
can be ignored.  
 
Once you have converged estimates of the trial weights hw , the eighth step is common 
to all meta-analyses. It is to calculate the standard error of the estimated parameterTÖ , 
simply by 
2/1
1
Ö

 ¹¸
·
©¨
§ ¦H
h
hwTV       (7) 
 
so that an approximate two-sided  D1100 %  confidence interval for TÖ  is given by 
 
TD VT Ö2/1Ö r z         (8) 
 
4. A MORE GENERAL SUMMARY MEASURES APPROACH 
The eight steps outlined above, hold specifically for the situation in which 
independence, normality and homoscedasticity can be assumed. When the 
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assumptions of independence and homoscedasticity no longer hold, the first five steps 
need to be modified. That is, (i) an appropriate SD for scaling the absolute mean 
difference must be chosen, (ii) an estimator for this SD found, (iii) the sampling 
distribution for this SD estimate determined, in order to obtain the relevant degrees of 
freedom, (iv) a bias relating to the choice of SD estimator calculated, and (v) the 
sampling distribution of the SMD estimate determined in order to obtain an unbiased 
summary statistic and its exact standard error. The final three steps (six to eight) are 
the same as in any meta-analysis of SMDs. 
 
4.1 Choice of SD for Scaling the Absolute Mean Difference 
A general population SMD can be defined as 
den
SMD V
PPT 01   (9) 
 
with the form of denV depending on the choice of standardising SD. As we have seen, 
in relation to &RKHQ¶V d and HeGJHV¶ g , VV  den IRUWKHVWDQGDUG60')RU*ODVV¶[2]  
SMD, the standardising metric is the control arm SD ( 0VV  den , where VV z0 ). For 
+X\QK¶V [12] SMD, the standardising metric is a simple average of the treatment and 
control arm SDs (  denV    22021 VV  ). And for White and Thomas¶ [8] or Hedges¶
[9] SMDs, the standardising metrics are the total, within or between cluster SDs 
respectively (  denV TV , WV  or BV ). The issue faced when pooling SMDs from trials 
with treatment-related clustering is the presence of between-arm heteroscedasticity. 
Here, the need for a common metric across arms results in two options. The first is a 
metric that has a direct interpretation. 2QHRSWLRQLV*ODVV¶60'DQRWKHULVD60'
based on the baseline SD. Here, the standardising metric has a clear interpretation but 
only where trial designs are comparable. The second is a metric that requires pooling 
potentially different population SDs. This could be the within, between or total SDs. 
We argue that the most general standardising SD is what we will refer to as the pooled 
total SD. The population SMD based on this is given by 
13 
 
   
2
11
01
2
00
2
11
01


 
nn
nn TT
ptota l VV
PPT        (10) 
 
It applies to fully-nested trials with treatment-related clustering but reduces to a range 
of other SMDs in more restrictive scenarios. For partially-nested trials, the total SD in 
the control arm is the standard control arm SD so 00 VV  T  in Equation (10). If the 
sample size is unequal across arms in the Behrens-Fisher case 00 VV  T and 11 VV  T  
in Equation (10). If the sample size is equal in this case then Equation (10) reduces to 
+X\QK¶V [12] SMD. If the sample sizes, within and between cluster SDs are all equal 
across the arms, then Equation (10) reduces to White and Thomas¶[8] and Hedges¶[9] 
SMD based on TV . Consequently, all these metrics can be viewed as special cases of 
the more general metric proposed here, making the pooled total SMD an appealing 
option, compared to a SRROHGµZLWKLQ¶RUSRROHGµEHWZHHQ¶60'. We will return to 
this issue in the discussion. 
 
4.2 Choice of Estimator for the Standardising SD  
White and Thomas [8] and Hedges [9] both give two options for estimating the total 
SD. Either it is estimated directly using the total SD ( Ths ) in every trial ( Hh ,,1 ), 
or if clustering is ignored in published analyses, and estimates of the total SDs are not 
readily available, it is estimated indirectly using the naïve SD ( hsx ), given, as with the 
standard case (Equations (2) and (4)), by the total mean squares. Sample estimates of 
the pooled total SD for the fully nested case are therefore given by 
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respectively, where khSSW and khSSB are sums of squares within- and between-clusters 
in each arm ( 1,0 k ) of every trial ( Hh ,,1 ), assuming cluster sizes are equal 
within trial arms. The sample SD in both Equations (11) and (12) is now a linear 
combination of mean squares terms rather than simply a single mean squares term (i.e. 
the mean square error) as it was assuming independence and homoscedasticity. 
Estimators of the pooled total and naïve SD are given in Table I, in terms of the sums 
of squares (SS), for the fully nested case and under the more restrictive scenarios. 
Note that the term for the total mean squares is biased for the pooled total variance, 
where clustering is present (see Section 4.4 for details of the implications of this). 
 
[Insert Table I about here] 
4.3 Sampling Distributions for Estimators of the Standardising SD  
One consequence of the sample SDs in Equations (11) and (12) now being linear 
combinations of mean squares terms is that their sampling distributions are also no 
longer exactly proportional to chi-squares with 201  hh nn  degrees of freedom hdf . 
Instead, they have sampling distributions approximately proportional to chi-squares 
with degrees of freedom given, using a Satterthwaite approximation [46] by  
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respectively, where h0ÖU and h1ÖU are estimated control and treatment ICCs respectively, 
2
Wkhs estimated within-cluster variances, khm the cluster size, khC the number of clusters 
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and 2khs  the naïve variances in arm 1,0 k  of trial Hh ,,1 . Derivations are given 
in Appendix A and B respectively as supporting web materials.  
 
It is possible to rewrite Equation (13) in terms of total variances by replacing  2Wkhs  
 khTkh UV 12 . The degrees of freedom given in Equations (13) and (14) simplify under 
more restrictive scenarios to those summarised in Table II. Under independence the 
degrees of freedom are equal for the pooled total and naïve variances. Huynh [12 
p.21] gave the degrees of freedom for his pooled SD. We give the degrees of freedom 
for the more general Behrens-Fisher situation but also those valid under a random-
intercept model for the pooled total SD, correcting typographical errors in White and 
Thomas [8 p.151] and Hedges [9 p.364], and for the pooled naïve SD as given by 
Hedges [9 p.156], thereby correcting a further typographical error in White and 
Thomas [8 p.151]. 
[Insert Table II about here] 
4.4 Bias Relating to the Choice of SD Estimator 
The expectation of the pooled naïve variance under a two-level heteroscedastic model 
is given by 
 
         (15) 
 
 
with 00  hU  and 2020 hhT VV   where trials are partially-nested (see Appendix C under 
supporting web materials for the derivation). Under independence, where 001   UU , 
it can be seen that 1 hb  and the naïve SD is unbiased. Hedges [9] gave the bias under 
a random intercept model as  
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mb U     (16) 
As before, the bias in Equation (16) is a special case of that given in Equation (15). In 
all cases, the naïve variance underestimates the total variance by a factor linked to the 
design effect. 
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4.5 Sampling Distributions of the SMD Estimates 
Huynh [12 p.4-6] and Hedges [9 p.360-2] have derived sampling distributions for 
large-sample H[WHQGLQJ&RKHQ¶V d ) and unbiased (extending HeGJHV¶ g ) estimators 
of SMDs based on pooled and total SDs, respectively. These have a similar form and 
can be extended to give yet more general sampling distributions for the pooled total 
SMD. Suppose that, for each of h  trials, the absolute mean difference in outcome 
observed between the treatment and control arms is distributed as 
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where the expectation ( > @hh yyE 01  ) and sampling variance ( 2 01 hh yy V ) of the absolute 
mean difference are unknown but the   khkhTkh ma U11   denote known constants. 
If > @ hhdenptotal bsE /2 ,2  V , where hdens , is given by Equation (11) or (12) and hb , given in 
Equation (15, also a known constant), the large-sample estimator of ptota lT  is given by 
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hh
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where 
hhdft M, is a non-central t-distribution with degrees of freedom hdf  given in Table 
II and non-centrality parameter equal to  2
,
2
01
Ö
hdenyyptota lh ss hh TM . A derivation for 
Equation (18) is given in Appendix D as supporting web materials.  
 
Again Equation (18) simplifies. In the standard case, Equation (18) is simply &RKHQ¶V  
d ( 001   UU , 1 Tkha , 1 hb , 2021 VV  ,   2 ,2 01 hdenyy ss hh hh nn 01 11  ). It is +X\QK¶V 
[12 p.4] g where 1 Tkha , 1 hb , and 2 ,2 01 hdenyy ss hh LVHTXDOWR+X\QK¶V 2k . It is White 
and 7KRPDV¶ [8 p.150] ung if 1 hb , 2021 BB VV  , 2 02 1 WW VV  and > @GVarss hdenyy hh   2 ,2 01 , 
i.e.  01 11 hhh nndeff   or 0011 hhhh ndeffndeff  . Finally, Equation (18) is +HGJHV¶ [9 
p.360] D  where Tkhaa  , 2021 BB VV  , 2 02 1 WW VV   and 2 ,2 01 hdenyy ss hh is equal to his Na ~ . 
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It follows from the definition of a non-central t-distribution (see Huynh [12 p.4] and 
White and Thomas [8 p.150]) that, where 2!hdf , 
> @  hSMDhLS dfcE TT  ,Ö  and 
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with the asymptotic standard error of hLS,ÖT  given by 
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correcting typographical errors in Huynh [12 p.5] and Hedges [9 p.361]. Note that, in 
Hedges [9], hhh cbdf 2 due to his XVHRI%R[¶V [47] JHQHUDOLVDWLRQRI6DWWHUWKZDLWH¶V
approximation [46] for the degrees of freedom. The result in Equation (19) implies 
that the unbiased estimator of ptota lT  is 
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Note that the adjustment White and Thomas [8] recommend for HeGJHV¶ g (Equation 
(5)) has been made to the estimated standard error in Equation (21).  
 
Where 2!hdf , the expectation and sampling variance for the general unbiased SMD 
estimate are given by Huynh [12 p.6] and White and Thomas [8 p.143] respectively as 
SMDT  and     > @ 222 ,22 012 SMDSMDhdenyyhhh ssdfdfdfc hh TT   . Given that the degrees of 
freedom are approximate so is the estimated standard error. It is worth noting that the 
accuracy of Satterthwaite [46] approximations may depend on the imprecision of the 
estimated component parameters. Equation (21) again simplifies. It is +HGJHV¶ g  in 
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the standard case. It is +X\QK¶V [12 p.6] h  in his case. It is :KLWHDQG7KRPDV¶ [8 
p.150] a djg in their case and it is +HGJHV¶ [9 p.362]  cbDJ /2  in his. 
 
The sampling distributions of the SMD estimators considered further in this paper are 
given in Table III. It can be seen that clustering and heteroscedasticity affect the trial 
SMD estimate and its standard error via the degrees of freedom, the trial SMD 
estimate via the denominator and its associated bias (where applicable), and finally, 
the standard error via 2
,
2
01 hdenyy ss hh . 
[Insert Table III about here] 
 
5. META-ANALYSIS METHODS USING THE IPD 
Any IPD meta-analysis will require the systematic reviewer to obtain the trial datasets 
in which patients are linked to trials, interventions and outcomes. If clustering by care 
provider is also to be considered, provider identifiers linking patients to providers will 
additionally be required. Assuming all necessary data are available, the first step is to 
prepare the data for analysis and the second step is to fit the associated meta-analysis 
model.  
 
5.1 Data Preparation 
In preparing the data, Goldstein et al [24] suggest that it is necessary to standardise 
the outcome, giving it a common origin and metric. Firstly, by subtracting the mean in 
the control arm from observed patient-level outcomes, the outcomes within trials are 
given a common origin, transforming them to differences from this origin. This is 
important when trials use different measurement scales since standardised means, like 
absolute means, are expected to vary from trial to trial [24]; it is differences between 
standardised means that are assumed to be comparable. If measurement scales are the 
same across trials, the outcomes would already have a common origin, making this 
unnecessary [24]. Secondly, by dividing the differences by a common SD, outcomes 
are given a common metric. If the interpretation of an SMD is to be meaningful its 
metric should not be confounded with the mean differences within the trials (see 
Greenland [48] for a similar argument regarding standardised regression coefficients). 
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For this reason, the standardising metric must be common to all arms of a trial. In the 
standard case, where independence and common variance assumptions hold, the data 
would therefore be transformed, prior to analysis, as follows 
h
hikhdsCohen
ikh
s
yyy
x
 0'      (22) 
 
where ikhy is the outcome for patient i of treatment arm k  of study h , hy0  is the mean 
in the control arm and hsx  the standardising metric from Equation (12). 
 
Goldstein et al [24] assumed that the population value of the SD is known, and equal 
to the sample estimate, thereby ignoring +HGJHV¶ [15] small-sample bias. If all trials 
have large effective sample sizes, as in their example, this will have little impact, but 
as previously discussed it will lead to bias otherwise, even where the total sample size 
is large. This can be avoided by first dividing the metric by its correction factor  hdfc  
using Equation (4) as follows 
 20'
hsh
hikhgHedges
ikh dfcs
yyy
xx
      (23) 
 
A similar transformation would be appropriate in the simple Behrens-Fisher situation. 
The difference here is that the divisor hsx  is now a linear combination of mean square 
terms so the degrees of freedom are not simply 201  hh nn  as they are for Equation 
(23) but are taken from Table II. 
 
In their example of studies of small versus large class size, where students are nested 
within classes, schools and studies, with schools crossed with interventions, Goldstein 
et al [24] suggested the following transformation, 
W
hjijkhCrossed
ijkh
s
yy
y 0
       (24) 
 
where ijkhy is the outcome for patient i  in school j  of treatment arm k  of study h , 
hjy 0  is the cluster-level mean in the control arm and Ws  the standardising metric. By 
standardising at the cluster-level, Goldstein et al [24] adopted a cluster-specific or 
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conditional approach. This is only possible because their studies had a crossed design 
(whereby schools had small and large class sizes) so absolute mean differences could 
be calculated at either the school or study level. Summary measures meta-analyses 
adopt a population-average or marginal approach, defining the origin at the trial-level. 
Defining the origin at the trial-level is necessary for nested designs as well since 
clusters relate only to one treatment arm. In line with their cluster-specific approach, 
Goldstein et al [24] used the within-cluster or level-1 SD as the metric within trials. 
They therefore implicitly assumed a random-intercept or random-coefficient model 
for the trials. 
 
Where clusters are nested within interventions, as in our example, we suggest 
subtracting the marginal mean hy0  rather than the conditional mean hjy 0  from ijkhy . To 
be consistent with a two-level heteroscedastic model for the trials, we suggest as 
previously the relevant common metric is the pooled total SD within trials. Again, the 
small-sample bias can be avoided by dividing this metric by its correction 
factor  hdfc  using Equation (4), with respect to the degrees of freedom in Table II. If 
the total SDs are used the transformation we suggest is simply, 
  ¸¸¹·¨¨©§  xx hT hijkhsTota lPooledijkh s yydfcy hT 02      (25) 
 
If the total mean squares are used, then it becomes, 
   ¸¸¹·¨¨©§  xx h hijkhhsNaivePooledijkh s yybdfcy h 02    (26) 
 
5.2 Meta-Analysis Models 
Once the outcome data have been transformed, the next step is to fit the appropriate 
model. Suppose iy is the transformed outcome for the 
thi patient, where Ni ,,1 , 
and that it is normally-distributed. Suppose also that hD  represents the standardised 
mean outcome in the control arm of trial h  (a fixed effect), and į is a fixed treatment 
effect with iK  being an indicator variable for the intervention versus control arm. 
UVLQJ*ROGVWHLQ¶V[49] notation for random effects, the standard fixed-effects meta-
analysis model would be 
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)1(
iihi eKy  GD      (27) 
 
where and )1(ie  represents the level-1 random effect for patients and  1,0~)1( Nei . We 
suggest that in the standard case (see Equations (22) and (23)), the following random-
effects meta-analysis model should be fitted, 
 
)1()2(
)( iiitria lihi eKKy  WGD       (28) 
 
where )2( )(itria lW  represents the level-2 random effect mapping patients to trials and 
 2)2( )( ,0~ WW Nitria l . Here, the trial effect is fixed but the treatment effect randomly 
varies across trials. In contrast to a fixed-effects meta-analysis model, Equation (28) 
respects the method by which data were standardised (accounting for the dependence 
induced by the data-driven transformation), defining the origin and metric at a trial-
level. A fixed-effects meta-analysis model would be appropriate if outcomes were 
standardised across trials using 0y  as the origin and xs  as the metric. However, 
defining the origin and metric at a meta-analysis level would only be appropriate if 
outcomes are standardised but measured with the same scales and standards across 
trials. This is relatively uncommon and not the case in our motivating example. 
 
When the pooled within-treatment standard deviation hsx  is used in the context of the 
Behrens-Fisher problem, one possible parameterisation of the appropriate random-
effects meta-analysis model is 
 
  iiiiiitria lihi KeKeKKy )1(1)1(0)2( )( 1  WGD      (29) 
 
where ike  are patient-level random errors for the control and treatment respectively 
and  20)1(0 ,0~ el Ne V  and  21)1(1 ,0~ el Ne V  with     12/11 10211200   nnnn ee VV . 
Model (29) is appropriate because it respects the fact that the data were standardised 
with a pooled patient-level SD. 
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If, as described in Equations (25) and (26), the pooled total hTs x or the pooled naïve 
hsx  SDs are used for meta-analysing fully-nested designs, we suggest extending 
Model (29) to allow for clustering within the trials under a common two-level 
heteroscedastic model for the trials, as follows 
     iiiiiitherapistiitherapistiitria lihi KeKeKuKuKKy )1(1)1(0)2( 1)()2( 0)()3( )( 11  WGD    (30) 
 
where )2( 0)(itherapistu  and 
)2(
1)(itherapistu  are random intercepts for therapist j  in the control 
and intervention arms, respectively, with  20)2( )(0 ,0~ ultherapist Nu V ,  21)2( )(1 ,0~ ultherapist Nu V  
and 010  uuV . Here, the level-2 and level-1 variances are allowed to differ between 
arms. It is the average of the total variances, i.e.      2121120200 11 eueu nn VVVV   
2/ 10  nn , that is equal to 1 now. It is important to note that Model (30) assumes 
the therapist ICC is equal across trials within arms. As we showed in our paper on the 
meta-analysis of absolute mean differences [25], this may be a strong assumption. 
 
The assumption of between-trial homogeneity in the therapist ICC is more clearly 
respected when the data are standardised using the pooled naïve SD because the ICC 
used in the degrees of freedom and bias correction in Equation (26) can be taken from 
the pooled estimate across trials. When the pooled total SD is used directly (Equation 
(25)), an unstructured random structure is implicitly assumed. More complex models 
could be fitted, in theory, such as meta-regressions of the random parameters (see 
[25]), but for simplicity they were not considered here. If all trials are partially nested, 
)2(
0)(itherapistu is constrained to zero, and the term omitted from Model (30). 
 
Where it is appropriate to assume a common random intercept model across trials, as 
may be the case for cluster randomised trials, Model (30) simplifies to 
 
)1()2(
)(
)3(
)( iiclusteriitria lihi euKKy  WGD        (31) 
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6. APPLICATION TO THE MOTIVATING EXAMPLE 
Short-term outcomes relating to the BDI [5], the GHQ [36], the HADS-D [3] and the 
Symptom Index were available for 850 patients from seven [29-35] counselling in 
primary care trials. Of these, 494 (58%) were allocated counselling with one of 56 
counsellors. Overall, the cluster sizes ranged from 1 to 47, with a median of 4.5 and 
an interquartile range of 2-10.5. Data were available for five or more patients for 33 of 
the counsellors. Table IV gives descriptive statistics for the seven included trials. The 
total mean squares (i.e. the pooled naïve variance) and the pooled total variance 
estimates are similar indicating the bias arising from using the pooled naïve SD to 
estimate the pooled total SD is likely to be minimal here. The published meta-analysis 
used a slightly different subset of patients as we excluded 18 patients with missing 
counsellor identifiers from all analyses. 
 
[Insert Table IV about here] 
 
6.1 Summary-Data Meta-Analyses 
Sample estimates of parameters used in estimating the SMDs are given in Table V. 
ANOVA estimates of the counsellor ICC range from -0.14 to 0.29. The possibility of 
negative ICC estimates arises as ANOVA estimation is consistent with a common 
correlation model rather than a variance components model [50]. By definition, the 
lower bound on the ICC is zero for a variance components model because a between-
cluster variance cannot be negative. It is the design effect that cannot be negative in 
ANOVA estimation. Design effects based on the raw ICCs range from 0.20 for 
Hemmings [33] to 1.73 for Harvey [32]. The negative ICCs found here are likely to be 
a consequence of sampling error arising from limited counsellors per trial and a small 
population ICC. As no evidence of heterogeneity was found in the ICCs between 
trials [51], to simplify our summary-data meta-analyses, we assumed a common 
counsellor ICC of 0.022, using a weighted average of these throughout, regardless of 
the model. We will return to this assumption in the discussion. Using this assumed 
fixed ICC, design effects vary from 1.04 for Chilvers [30] to 1.80 for Hemmings [33]. 
To reflect a general lack of knowledge about cluster size distributions, we assumed 
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equal cluster sizes as well. This assumption is questionable, as a few counsellors were 
responsible for the majority of counselling in Chilvers [30] and King [34]. 
 
[Insert Table V about here] 
 
Table V gives sample estimates for Satterthwaite degrees of freedom, Hedges small-
sample bias and the bias associated with the choice of estimator for the standardising 
metric for each case and for each included trial. The degrees of freedom drop for the 
Behrens-Fisher, pooled total and pooled naïve cases compared to the standard Hedges 
g. However this has limited impact, with the correction factor for the small-sample 
bias, c(df), being close to one and generally unaffected by the choice of model. As we 
expected, comparing the total mean squares and pooled total variance, the correction 
factor for using the naïve SD is also close to one: it is precisely one in all other cases. 
 
Table VI gives summary-data estimates and associated standard errors for fixed- and 
random-effects meta-analyses of SMDs based on four standardising metrics: Hedges g 
is the standard case against which the Behrens-Fisher, pooled total and pooled naïve 
cases are compared. We also present the impact of iterating estimates of the standard 
errors for the weights, giving the estimates and associated standard errors from both 
the initial (i.e. not iterated) and iterated models. Using the reduced dataset and fixed-
effects meta-analysis, the initial standard pooled SMD was estimated to be -0.24 (SE 
= 0.013; 95% CI -0.27 to -0.22) while the iterated equivalent was -0.26 (SE = 0.072; 
95% CI -0.40 to -0.12), similar to the published result (SMD= -0.24, 95% CI -0.38 to 
-0.10). This highlights the importance of iterating here, as the standard error of the 
pooled SMD is underestimated initially, leading to over-precise confidence intervals. 
 
[Insert Table VI about here] 
 
The pooled SMD and its associated standard error are similar for the fixed-effects 
models for all four SMDs, increasing only slightly for the Behrens-Fisher, pooled 
total and pooled naïve cases compared to the standard case. The recommended model 
in each case is a random-effects meta-analysis model. Initial and iterated estimates are 
much more similar here. The pooled SMD and its associated standard error are also 
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almost identical across the four cases as well. This is because the between-trial 
variance dominates. A possible explanation for this is differences in the counselling 
provided and in the patients included across trials.  
 
One reason for the limited impact of accounting for treatment-related clustering in the 
summary-data meta-analyses could be the size of the ICC assumed. So we performed 
a sensitivity analysis, increasing the assumed ICC in analyses reported in Table VI. 
The conclusions remain unchanged. However, as expected and contrary to trial 
estimates of absolute mean differences [25], trial estimates of SMDs were pulled 
towards the pooled treatment effect estimate as the ICC increased, although not 
perceptibly in the range of the ICC expected here. Random-effects meta-analysis 
estimates remained more stable than their fixed-effects counterparts, providing further 
support for the conclusion that treatment-related clustering has more impact on fixed-
effects than on random-effects meta-analyses. The DerSimonian-Laird estimate of the 
between-trial variance increased until the ICC was in mid-range, decreasing again up 
to its maximum, illustrating that the total and naïve SMDs are a function of the ICC. 
The cluster sizes were known in our example. If the cluster sizes had been assumed, 
further analyses would be recommended to assess the sensitivity of the conclusions to 
these assumptions.   
 
6.2 IPD Meta-Analyses 
In contrast to summary-data meta-analyses, those based on IPD make it practical to 
relax assumptions relating to the cluster size distribution. They also make it clearer 
what is being assumed. Data were prepared separately for each case using the relevant 
degrees of freedom and correction factors for (i) the small-sample bias and (ii) bias 
associated with the choice of estimator for the standardising metric using Equations 
(25) and (26). IPD models were implemented using Restricted Maximum Likelihood 
(REML) [49] with the mixed command in Stata 13 (see Table VII) and with Restricted 
Iterative Generalised Least Squares (RIGLS) [49] in MLwiN. Both gave comparable 
results. Details of programming code for Stata are given as supporting web materials. 
 
[Insert Table VII about here] 
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Table VII gives IPD estimates and associated standard errors for fixed- and random-
effects meta-analyses of SMDs based on the four standardising metrics as before. The 
IPD counterparts to the summary-data estimates reported in Table VI are very similar 
(Table VIII gives a summary of the summary-data and IPD results), with the standard 
pooled SMD from the fixed-effects meta-analysis being -0.261 (SE = 0.071; 95% CI -
0.40 to -0.12). This indicates that little is gained by using a full-likelihood approach 
and accounting for variability in cluster sizes here. The patient-level variance estimate 
is 0.992. To interpret the SMD in SD units, this should be precisely equal to one. That 
it is not suggests the SMD is slightly under estimated, as -0.261/0.992 = -0.263. The 
same can be said for the standard random-effects estimate, where Model (28) applies: 
here -0.263/0.987 = -0.266.  
 
[Insert Table VIII about here] 
 
In the Behrens-Fisher case, the appropriate model explicitly allows for between-arm 
heteroscedasticity at the patient-level. The relevant SMD is the H[WHQVLRQRI+X\QK¶V 
[12] SMD that allows for a ratio of sample sizes between arms other than one. Boot et 
al [29], Harvey et al [32] and Hemmings [33] all had unequal sample sizes favouring 
the counselling arm, making this issue pertinent to this example. Under the random-
effects model given in Model (29), the pooled SMD was estimated to be -0.263 (SE = 
0.093) with the IPD. In this case, it is the average of the patient-level variances i.e. 
((494-1)*0.867+(356-1)*1.153)/(850-2)=0.987 that defines the metric. This again 
implies that the SMD is slightly under-estimated, as -0.263/0.987=-0.266.  
 
In the pooled total and pooled naïve cases, the appropriate model explicitly allows for 
between-arm heteroscedasticity at the counsellor- and at the patient-levels. Estimates 
from the random-effects meta-analysis model given in Model (30) are identical, with 
the pooled SMD estimated to be -0.264 (SE = 0.092). Under this model, the metric is  
((494-1)*(0.842+0.035)+(356-1)*1.154)/(850-2)=0.993 for the pooled total case and 
((494-1)*(0.841+0.037)+(356-1)*1.151)/(850-2)=0.992 for the pooled naïve case. It is 
therefore close to one, with the final SMD estimated to be -0.264/0.993=-0.266 (SE = 
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0.092; 95% CI -0.45 to -0.09) in favour of the counselling arm. This indicates that 
counselling reduces short-term mental health symptoms by an average of 0.266 SDs 
compared to no counselling and that this reduction remains statistically significant at 
the 5% level. According to Cohen [13], an effect size of 0.2 equates to a small effect. 
The confidence interval is wide including moderate effect sizes as well as trivial ones. 
Heterogeneity in the size of effects between counsellors and trials suggests that more 
could be done to optimise counselling in primary care. 
 
7. DISCUSSION 
As we have highlighted, the meta-analysis of SMDs is more complicated than that of 
absolute mean differences (see [25]), especially where clustering associated with care 
providers is probable. This is partly because an SMD is a ratio and partly because its 
denominator is also estimated. This leads to the data-driven transformations seen in 
the IPD case. So, in contrast to the meta-analysis of absolute mean differences, use of 
a fixed effects meta-analysis model is less defensible, summary statistics are biased in 
small samples [6, 15], their sampling variance depends on the population parameter 
(see Equation (4)) and their sampling distribution follows a non-central t-distribution 
(Equation (18)). These are true of all meta-analyses of SMDs. Where there is 
between-arm heteroscedasticity in provider and patient level variances, the size of the 
SMD, its small-sample bias, its sampling variance and interpretation additionally 
depend on the choice of standardising metric.  
 
A general approach has been described which allows for treatment-related clustering 
in the meta-analysis of normally-distributed outcomes from randomised trials with 
two-level nested designs. Building on the work of Hedges [9], Huynh [12], Goldstein 
et al [24] and White and Thomas [8], we have recommended a pooled total SD as the 
standardising metric, using the pooled naïve SD to estimate this where a pooled total 
SD is not available in trial reports. The advantages of the pooled total SMD are that i) 
it is general, in the sense that it encompasses +HGJHV¶, +X\QK¶V and White and 
7KRPDV¶HVWLPDWRUVDVVSHFial cases, allowing the assumptions of independence and 
common variance to simultaneously be relaxed within trials but also their sample 
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sizes to differ across arms, ii) it can be estimated using the pooled naïve SD where 
published data is limited and iii) its interpretation is comparable across trial designs, 
allowing extensions for pooling mixed trial designs. 
 
In our example, all trials had partially-nested designs, so that the counsellor variance 
was equal to zero in the control arm. Some of the trials also had unequal sample sizes 
across arms. As a result, the methods described by White and Thomas [8] and Hedges 
[9] could not be applied. In the context of the IPD, a random-intercept model could 
have been assumed for the trials, but a choice would have had to be made between 
including patients in the control arm as clusters of size one or as clusters of size 0hn . 
If clusters of size one were used, the within-cluster SD would not be defined for the 
control arm and would be estimated solely within the treatment arm; the between-
cluster SD would be available in both arms, but it would unlikely be equal. If clusters 
of size 0hn  were used, the between-cluster SD would not be defined in the control arm 
and would be estimated solely from the treatment arm. Also while the within-cluster 
SD is available in both arms, the number of clusters is unequal, giving greater weight 
to the treatment arm. In neither case is a random-intercept model appropriate. 
 
:HFRXOGKDYHH[WHQGHG*ODVV¶60'[11], using the control arm SD as the metric of 
choice. This option was initially quite appealing for our example as the point estimate 
would be independent of treatment-related clustering, minimising impact of between-
trial heterogeneity in the ICC. The drawback became clear when the corresponding 
IPD meta-analysis model was considered. If the control arm SD is used as the metric 
then the denominator of the ICC is the patient SD in the control, not treatment, arm. 
This mis-specifies the variance-covariance structure of the two-level heteroscedastic 
model assumed for the trials and makes interpretation of random effects less straight-
forward. The proposed SMD based on the pooled total SD addresses these limitations. 
 
Using our proposed metric for our example of counselling in primary care, we found 
that the impact of treatment-related clustering on the pooled SMD estimate and its 
standard error was not important. Our sensitivity analyses for the meta-analysis 
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published by Bower and Rowland [28] did not change their conclusions. In hindsight, 
the reasons for this are obvious: (i) the ICC and the cluster sizes were both small, so 
the variance inflation factors were small, (ii) a larger number of patients were 
allocated to counselling compared to no counselling, and (iii) the between-trial 
heterogeneity in the treatment effect was dominant. It is therefore unsurprising that 
the conclusions of the published meta-analysis remain unchanged.  
 
However, on top of this, in our summary-data meta-analyses, we assumed the 
population counsellor ICCs were the same across trials, and equal to our pooled 
estimate. Making this assumption simplified our analyses but it is clearly a limitation 
of our approach. It was motivated by separately finding no evidence of heterogeneity 
[51]. Further work is needed to explore the implications of allowing the ICCs to vary 
across trials, and of using (truncated) ICC estimates in such analyses, where this 
assumption is not reasonable. Although it is unlikely that the conclusions of the meta-
analysis would change if a more complex summary-data model had been fitted, it is 
possible that this contributed to the limited impact of treatment-related clustering 
observed here. Impact may not be limited in general, however. While treatment-
related clustering has historically rarely been taken into account in trials, it is now 
recommended that it is considered in trials of non-pharmacological treatments [52]. 
Similar broad guidance is made by Cochrane [53] with regard to meta-analyses, 
although the methods are just becoming available. This paper contributes to the 
literature supporting the uptake of this guidance. 
 
A key assumption made in all meta-analyses of SMDs is that patient outcomes are 
normally-distributed within trials. This assumption allows the standardising metric to 
be distributed proportionally to a chi-square with known degrees of freedom in the 
standard case, and with degrees of freedom given using a Satterthwaite approximation 
otherwise. Further work is needed to explore the impact of departures from normality. 
Alternative approaches might also be investigated, such as the use of robust estimates 
of the variance of the standardising metric, particularly for small samples. Another 
DVVXPSWLRQLVWKDW+HGJHV¶VPDOO-VDPSOHELDVVKRXOGEHFRUUHFWHGIRUXVLQJ+HGJHV¶J
LQVWHDGRI&RKHQ¶VG In moderate to large samples this will be unimportant, but it is 
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the effective sample size rather than the number of observations that determines the 
LPSDFWRIWKLVELDVVRZKHUHWKH,&&RUFOXVWHUVL]HLVODUJH+HGJHV¶FRUUHFWLRQPD\
still be important. 
 
Our IPD meta-analyses start to show how the model chosen depends on the choice of 
metric. Specifically we explored the relationship between the choice of metric and the 
model that preserves the interpretation of that metric. We found the metric implied by 
each model was not precisely what we expected, which implies that there is a further 
bias not identified here. In the standard case, we suggest that a random-effects meta-
analysis model is appropriate since the SD estimate tends to be trial-specific. For the 
Behrens-Fisher case, we suggest the metric and model should reflect heterogeneity in 
the patient SD across arms. For nested designs with treatment-related clustering, we 
propose that the patient and cluster-level SDs should be allowed to vary across arms. 
Where this was so, we expected the relevant SD estimated from the model to equal 
one, so the SMD can simply be interpreted as a mean difference given in SD units and 
the counsellor variance directly estimates the counsellor ICC. Two explanations for 
this disparity could be explored further. The first relates to the relative weighting of 
data by the standardising SD and REML, the second to between-trial heterogeneity in 
counsellor ICCs affecting the standardising metric. Secondly, it also became clear that 
the model depends on the level at which data is standardised when contrasting our 
models with those proposed by Goldstein [24]. A population-average model is 
arguably more appropriate for meta-analysing nested designs. More work is needed to 
investigate the implications of this in meta-analyses incorporating treatment-related 
clustering, generalising the methods proposed by Bohning et al [54] and Viechtbauer 
[55]. Thirdly, it may not always be safe to assume a common origin across trials. If a 
random trial intercept was included in an IPD model, correlation can be estimated 
between heterogeneity in a SMD and its origin. While this is regarded as a nuisance in 
summary-data meta-analyses, it may be worth considering in IPD meta-analyses. 
Further work is needed to understand these issues more, and the potential biases 
associated with them. 
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The focus of this paper has been on meta-analyses of SMDs where all included trials 
are not only addressing the same research question, but also have comparable designs. 
In our motivating example, all seven trials had a partially nested design. It would be 
straightforward to extend the methods outlined here to situations where all the trials 
have fully nested designs. In both cases, the assumption of between-trial homogeneity 
in the random effects is arguably tenable. We have previously argued [25] that this is 
not the case for meta-analyses of mixed clustered trial designs. There, we argue ICCs 
vary not only between trial arms but also between trial designs. An implication of this 
for meta-analyses of SMDs is that the metric would vary systematically between trials 
with different designs. It becomes crucial that a metric has comparable interpretations 
across trial designs so variation in the size of the standardising metric is a reflection 
only of the use of different trial designs to address a common research question. It is 
important that these issues are considered if mixed trial designs are to be included in a 
meta-analysis: the general metric we have proposed is only half the story. Models that 
preserve the interpretation of that metric in different situations are also needed.  
In our motivating example, there was the potential for clustering by the GP. GP care 
tended to be a co-intervention, with GPs crossed with treatment arms. As GPs were 
not blinded, an interaction between GPs and treatment arm is plausible. Information 
on GP involvement was limited, however, with GP identifiers only recorded in one or 
two of the trials. We recommend future trials record identifiers for all significant care 
providers, whether they are delivering the trial intervention or not. This will enable 
meta-analysts to incorporate, or explore incorporating, trials with multiple therapist-
per-patient designs extending [56]. Our motivating example also included additional 
levels, in that repeated measures were available over time. As the follow-up periods 
included DV³VKRUW-WHUPRXWFRPHV´ranged from 6 weeks to 6 months, and most of the 
trials included more than one outcome visit, further work is planned to fit realistic 
meta-analysis models to the IPD available, building on this methodological work and 
that of others (e.g. [57] and [58]), aimed more at a clinical audience. 
 
None of the seven trials we included had accounted for treatment-related clustering in 
their published analyses. This made it important to take account of treatment-related 
clustering in our meta-analysis. If they had done so appropriately, then we would not 
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have needed to take additional account of it in our summary-data meta-analyses as the 
trial estimates and their standard errors could be pooled directly. IPD meta-analyses 
would remain as outlined however. As we had access to all of the relevant IPD, we 
had maximum flexibility. As we have shown here, the pooled treatment effect and its 
95% confidence interval are very similar for summary-data and IPD meta-analyses. 
Beyond standard access to sample sizes, means and SDs by trial arm, we assumed 
access to average cluster sizes and a range of realistic ICCs by trial arm. Based on our 
experience with our motivating example, these are likely to be readily available from 
trial reports and the more general literature (e.g. [59]). Use of the total mean squares 
(or naïve SD) typically reported is possible in place of the pooled total SD as we have 
described. 
 
In conclusion, in the presence of treatment-related clustering, meta-analysis of SMDs 
is more complicated than that of absolute mean differences, and hence more difficult 
to interpret, but it is possible if sufficient care is taken using the methods described 
here and extensions to these. Specific guidance is needed in the Cochrane Handbook 
to facilitate the uptake of these methods. The code used to program them in Stata is 
available from the first author on request.  
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